Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA

Marc J. Williams & Sohrab P. Shah et al. · 2025-10-01

Emergence of drug resistance is the main cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC)
Links
DOIPubMed
Journal
Nature
Institutions
Memorial Sloan Kettering Cancer CenterUnknown InstitutionIcahn School Of Medicine At Mount Sinai
Authors
Marc J. Williams, Michelle Wu, Nancy Varice, Duaa H. Al-Rawi, Hannah J. Lees, Jake June-Koo Lee, Matthew A. Myers, Matthew Zatzman, Nicole Rusk, Emily Ali, Ronak H. Shah, Michael F. Berger, Yulia Lakhman, Andrew McPherson, Dmitriy Zamarin, Brian Loomis, Britta Weigelt, Claire F. Friedman, Sohrab P. Shah
Funding
PathologyThe MSK Genomic Data Analysis Center for Tumor EvolutionMSK SPORE in Genomic Instability in Breast CancerSingle cell quantification of genomic instability in cancer as a determinant of therapeutic responseExploiting markers of genomic instability in high-risk pre-invasive ovarian cancerPOTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION

NCI NIH HHS

P30 CA008748

NCI NIH HHS

U24 CA264028

NCI NIH HHS

P50 CA247749

NCI NIH HHS

K99 CA256508

NCI NIH HHS

R01 CA281928

NCI NIH HHS

R01 CA269382